https://www.selleckchem.com/pr....oducts/empagliflozin
We read with interest the article by Matza et al on ustekinumab in giant cell arteritis (GCA) recently published in Arthritis Care and Research (1). The rationale for using ustekinumab in GCA is that it targets the Th1 and Th17 pathways felt to be centrally involved in GCA pathogenesis, potentially impacting at a more proximal stage than other agents such as tocilizumab (4). It is encouraging to see efforts to explore alternative treatment options for GCA, however we believe a number of aspects of this study require furthe
Like
Comment
Share
